FDA Approves Pivotal Trial for Novel Tricuspid Valve Repair Device MIA-T
核心洞察
The FDA has approved Micro Interventional Devices (搜索)' MIA-T (搜索) system for pivotal clinical trial use, marking a significant milestone for percutaneous tricuspid valve repair technology.
The STTAR-US trial will evaluate MIA-T (搜索)'s proprietary PolyCor (搜索) anchors that reduce annular area and minimize tricuspid regurgitation (搜索) through 12F delivery catheters.
The device addresses a major unmet need, as 1.6 million Americans suffer from tricuspid regurgitation (搜索) but only a small percentage are eligible for surgical treatment.
Micro Interventional Devices (搜索) (MID) has received FDA approval for Investigational Device Exemption (IDE) use of its MIA-T (搜索) (Minimally Invasive Annuloplasty – Tricuspid) system, enabling the company to launch its pivotal clinical trial at notable U.S. hospitals. The approval represents a critical advancement for percutaneous tricuspid valve repair technology, particularly for patients with limited treatment options.
Novel Approach to Tricuspid Regurgitation
The STTAR-US pivotal trial will evaluate MID's proprietary PolyCor (搜索)™ anchors, which are specifically engineered for cardiac tissue applications. These polymeric anchors are deployed into the tricuspid annulus (搜索) via 12F delivery catheters and are designed to treat functional tricuspid valve disease (搜索) by reducing annular area, minimizing tricuspid regurgitation (搜索) (TR), and encouraging natural healing.
The technology represents one of the first percutaneous annular repair devices in the emerging transcatheter tricuspid valve repair (TTVr) market. MIA-T (搜索) utilizes compliant PolyCor (搜索)™ anchors described as the world's first low mass polymeric implant designed to comply with normal physiological valvular function. The implant is engineered to plicate and comply with cardiac tissue once deployed.
Addressing Significant Unmet Medical Need
The approval comes at a time when significant unmet clinical needs exist in tricuspid regurgitation (搜索) treatment. According to the company, 1.6 million people in the United States alone suffer from TR, yet only a small percentage of these patients are eligible to receive surgical treatment. MIA-T (搜索) aims to address this large, untreated patient population and is positioned as unique among tricuspid repair and replacement technologies due to its versatility and capability to treat patients who are ineligible for surgical or transcatheter edge-to-edge repair (TEER) procedures.
Distinguished Clinical Leadership
The STTAR-US Steering Committee comprises thought leaders in the structural heart field. The trial will be led by two principal investigators: Dr. Bassem Chehab, Associate Professor of Medicine at the University of Kansas and Director of Structural Cardiology, Clinical Cardiology and Research at Ascension Health in Wichita, Kansas, and Dr. Saibal Kar, Program Director Cardiovascular Disease Fellowship at Los Robles Regional Medical Center (搜索) in Thousand Oaks, California, and National Physician Director, Interventional Cardiology for HCA Healthcare US.
Market Opportunity and Strategic Positioning
"This approval marks a critical milestone in the development of MIA-T (搜索). As one of the first percutaneous annular repair devices, we believe MIA-T will play a significant role in the emerging TTVr market," said Michael Whitman, Chief Executive Officer of Micro Interventional Devices (搜索). "The global market is projected to exceed $3 billion annually by 2027, with rapid growth expected as minimally invasive options advance and adoption increases."
Whitman emphasized the device's potential impact, stating, "With a rapidly growing global market and no established percutaneous standard of care for treating tricuspid regurgitation (搜索), we believe MIA-T (搜索) has the potential to deliver both meaningful patient outcomes and significant value for our stakeholders."
The company has been working closely with the FDA since receiving Breakthrough Technology Designation, which facilitated the regulatory pathway for this pivotal trial approval. MID is a privately held medical device company focused on developing percutaneous solutions for structural heart disease, with primary emphasis on repairing tricuspid and mitral valves through catheter-based approaches while the heart is beating, eliminating the need for sternotomy and cardiopulmonary bypass surgery.